Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma

Neuro-Oncology

Volumn 18, Issue 3, 2016, Pages 368-378

  Everson, Richard G ^a   Antonios, Joseph P ^a   Lisiero, Dominique N ^b   Soto, Horacio ^a   Scharnweber, Rudi ^a   Garrett, Matthew C ^a   Yong, William H ^b   Li, Ning ^a   Li, Gang ^a   Kruse, Carol A ^a,b   Liau, Linda M ^a,b   Prins, Robert M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; decitabine; engineered T cells; glioblastoma; immunotherapy

Indexed keywords

DECITABINE; NY ESO 1 ANTIGEN; AZACITIDINE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG CYTOTOXICITY; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN TARGETING; T LYMPHOCYTE; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; T-LYMPHOCYTES;

EID: 84960102710     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov153     Document Type: Article

References (21)

1. Mitchell DA, Sampson JH. Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics. 2009; 6(3):527-538.
2. Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol. 2010;2010:1-18.
3. Gomez GG, Varella-Garcia M, Kruse CA. Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. Cancer Genet Cytogenet. 2006; 165(2):121-134.
4. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-5525.
5. Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008;180(9):6116-6131.
6. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
7. Ramis G, Martinez-Alarcon L, Quereda JJ, et al. Optimization of cytotoxicity assay by real-time, impedance-based cell analysis. Biomed Microdevices. 2013;15(6):985-995.
8. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immuntherapy. Clin Cancer Res. 2011;17(6):1603-1615.
9. Konkankit VV, Kim W, Koya RC, et al. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med. 2011;9:192.
10. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-5239.
11. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134-144.
12. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129.
13. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3): 659-661.
14. Klebanoff CA, Gattinoni L, Palmer DC, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res. 2011;17(16): 5343-5352.
15. Guirguis LM, Yang JC, White DE, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother. 2002;25(1):82-87.
16. Powell S, Dudek AZ. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res. 2009;29(10):4189-4193.
17. Budhu S, Loike JD, Pandolfi A, et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med. 2010;207(1):223-235.
18. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133-151.
19. Kurschus FC. T cell mediated pathogenesis in EAE: molecular mechanisms. Biomed J. 2015;38(3):183-193.
20. Floris S, Ruuls SR, Wierinckx A, et al. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol. 2002;127(1-2):69-79.
21. Natsume A, Wakabayashi T, Tsujimura K, et al. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. 2008; 122(11):2542-2553.